132 Randomized between February 4, 2011 and May 4, 2012

Standard doses group (n=44)
- Month 0 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 1 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 2 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 6 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 7 anti-HBs (n=44)
- Month 12 anti-HBs (n=44)

4 doses group (n=44)
- Month 0 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 1 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 2 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 6 anti-HBs and received 20 µg recombinant HBV vaccine intramuscular (n=44)
- Month 7 anti-HBs (n=44)
- Month 12 anti-HBs (n=44)

4 double doses group (n=44)
- Month 0 anti-HBs and received 40 µg recombinant HBV vaccine intramuscular (n=44)
- Month 1 anti-HBs and received 40 µg recombinant HBV vaccine intramuscular (n=44)
- Month 2 anti-HBs and received 40 µg recombinant HBV vaccine intramuscular (n=44)
- Month 6 anti-HBs and received 40 µg recombinant HBV vaccine intramuscular (n=44)
- Month 7 anti-HBs (n=44)
- Month 12 anti-HBs (n=44)

Median duration of 49.7 months after completion of vaccine schedule

2 Declined to participate
n=42
1 Declined to participate
n=43
3 Declined to participate
n=41

Fig. S1. Consort diagram of the study participants